Castration-resistant prostate cancer (CRPC)

被引：0
|
作者：
Loidl, W. [1 ]
Luger, F. [1 ]
Roosen, A. [1 ]
机构：
[1] Krankenhaus Barmherzigen Schwestern, Urol Abt, A-4010 Linz, Austria
来源：
UROLOGE | 2014年 / 53卷 / 03期
关键词：
Prostatic neoplasms; Chemotherapy; Androgen synthesis inhibitors; Androgen receptor inhibitors; Biomarkers; DOCETAXEL PLUS PREDNISONE; ANTIANDROGEN; CHEMOTHERAPY; ESTRAMUSTINE; MITOXANTRONE; ABIRATERONE; SURVIVAL; EFFICACY; ARN-509;
D O I：
10.1007/s00120-013-3377-0
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
In merely a short period of time the comprehension of castration-resistant prostate cancer has evolved. It is now possible to clearly outline the exact definition and variance of the disease pattern. A wealth of new effective agents can be applied to extend the patient's life span and improve the quality of life. An understanding of the pharmacodynamics and side effects of each substance is of utmost importance for the practical application. In order to use these new medicines in a differentiated manner urologists require continuous education. The evaluation of response to treatment has yet to be satisfyingly verified. Molecular markers still need to be developed and evaluated.
引用
收藏
页码：391 / 399
页数：9
相关论文
共 50 条
  • [1] Castration-resistant prostate cancer (CRPC) [Kastrationsrefraktäres prostatakarzinom (CRPC)]
    Loidl W.
    Luger F.
    Roosen A.
    [J]. Der Urologe, 2014, 53 (3): : 391 - 401
  • [2] Mechanisms of resistance in castration-resistant prostate cancer (CRPC)
    Chandrasekar, Thenappan
    Yang, Joy C.
    Gao, Allen C.
    Evans, Christopher P.
    [J]. TRANSLATIONAL ANDROLOGY AND UROLOGY, 2015, 4 (03) : 365 - 380
  • [3] Role of Immunotherapy in Castration-Resistant Prostate Cancer (CRPC)
    Suarez, Cristina
    Morales-Barrera, Rafael
    Ramos, Victor
    Nunez, Isaac
    Valverde, Claudia
    Planas, Jacques
    Morote, Juan
    Maldonado, Xavier
    Carles, Joan
    [J]. BJU INTERNATIONAL, 2014, 113 (03) : 367 - 375
  • [4] CASTRATION-RESISTANT PROSTATE CANCER (CRPC): A UK EPIDEMIOLOGY STUDY
    Morgan, C.
    McEwan, P.
    Chamberlain, G.
    Cabrera, C.
    Parry, D.
    [J]. VALUE IN HEALTH, 2010, 13 (03) : A26 - A26
  • [5] DISEASE BURDEN OF CASTRATION-RESISTANT PROSTATE CANCER (CRPC) IN CHINA
    Ma, F. F.
    Liu, Q.
    Wang, J.
    Zhang, X. J.
    Yu, F.
    [J]. VALUE IN HEALTH, 2020, 23 : S451 - S452
  • [6] Novel therapeutics for the management of castration-resistant prostate cancer (CRPC)
    Lee, Daniel J.
    Cha, Eugene K.
    Dubin, Justin M.
    Beltran, Himisha
    Chromecki, Thomas F.
    Fajkovic, Harun
    Scherr, Douglas S.
    Tagawa, Scott T.
    Shariat, Shahrokh F.
    [J]. BJU INTERNATIONAL, 2012, 109 (07) : 968 - +
  • [7] Retreatment with docetaxel in metastatic castration-resistant prostate cancer (CRPC).
    Gernone, A.
    Pagliarulo, A.
    Pagliarulo, V.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [8] Second line therapy for castration-resistant prostate cancer (CRPC)
    Molitor, B.
    Boergermann, C.
    [J]. UROLOGE, 2012, 51 (03): : 357 - 362
  • [9] Castration-Resistant Prostate Cancer (CRPC): understanding the mechanisms and implications for management
    Bessede, T.
    Malavaud, B.
    Staerman, F.
    Culine, S.
    [J]. PROGRES EN UROLOGIE, 2013, 23 : 6 - 11
  • [10] COSTS AT THE END OF LIFE FOR PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER (CRPC)
    Alemayehu, B.
    Parry, D.
    Engel-Nitz, N. M.
    Kulakodlu, M.
    Nathan, F.
    [J]. VALUE IN HEALTH, 2011, 14 (03) : A161 - A162
12345